SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade by Romero, Octavio A. et al.
ARTICLE
SMARCA4 deficient tumours are vulnerable to
KDM6A/UTX and KDM6B/JMJD3 blockade
Octavio A. Romero 1,11✉, Andrea Vilarrubi 1,11, Juan J. Alburquerque-Bejar 1, Antonio Gomez 2,
Alvaro Andrades3,4, Deborah Trastulli 5, Eva Pros 1, Fernando Setien1, Sara Verdura5, Lourdes Farré 6,
Juan F. Martín-Tejera6, Paula Llabata 1, Ana Oaknin 7, Maria Saigi 1,8, Josep M. Piulats8,
Xavier Matias-Guiu9, Pedro P. Medina 3,4, August Vidal 9,10, Alberto Villanueva 6,10 &
Montse Sanchez-Cespedes 1✉
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex
commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient
tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with
SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to
the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired
transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX
and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its
inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice
orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell
carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In
this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be
exploited for treating SMARCA4-mutant cancer patients.
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Chromatin remodelling is one of the epigenetic processes thatis commonly disturbed in cancer, mainly through alterationsin the mammalian switch/sucrose non-fermentable (SWI/
SNF) complex. This complex modifies the structure of the chro-
matin by the ATP-dependent disruption of DNA–histone interac-
tions at the nucleosomes, thereby activating or repressing gene
expression. The various functions and components of the SWI/SNF
complex have been thoroughly reviewed elsewhere1,2.
Alterations at genes encoding different components of the SWI/
SNF complex are present in a variety of tumour types and are thus
an important feature of cancer development3. The SMARCA4 (also
known as BRG1) gene codes a core catalytic component of the SWI/
SNF complex that features a bromodomain and helicase/ATPase
activity1,2. Our own previous work produced the first evidence that
SMARCA4 is genetically inactivated in cancer and that SMARCA4
deficiency prevents the response to pro-differentiation stimuli in
cancer cells4–6. In lung cancer, SMARCA4 inactivation affects about
one-third of non-small cell lung cancers (NSCLCs) and pre-
ferentially occurs against a background of wild type MYC (either C,
L or N) or of members of the MYC-axis, such as MAX or MGA4–7.
This hints at the existence of an important network that connects
SWI/SNF and MAX/MYC functions. Mutations of SMARCA4 also
occur in other types of cancer, notably in the rare and very
aggressive small cell carcinoma of the ovary, hypercalcaemic type
(SCCOHT)8, in which SMARCA4 inactivation has been reported in
almost 100% of cases9–11.
The progress made towards understanding the role of chromatin
remodelling in cancer development highlights the great potential of
new epigenetic-based therapeutic strategies. With particular refer-
ence to SMARCA4, some previous studies have sought the vul-
nerabilities of SMARCA4-deficient tumours with a view to
exploiting them for cancer treatment. SMARCA4 and SMARCA2
are mutually exclusive catalytic subunits of the SWI/SNF complex,
and the inhibition of SMARCA2 activity appears to be synthetic
lethal in cancer cells carrying SMARCA4-inactivating mutations, an
effect that could be explained by paralogue insufficiency12,13. Fur-
ther, SWI/SNF-mutant cancer cells with a wild type KRAS back-
ground depend on the non-catalytic action of the histone
methyltransferase, EZH214. However, we currently know of no
small compounds that are capable of suppressing the ATPase or
non-catalytic functions of SMARCA2 and EZH2, respectively, so
these molecules are not yet suitable for use in therapeutic inter-
ventions. More recently, it has been proposed that cancer cells with
an inactive SMARCA4 may be susceptible to CDK4/6 inhibitors15.
On the other hand, components of the SWI/SNF complex bind
to various nuclear receptors (e.g., oestrogen, androgen, glucocorti-
coid and retinoid receptors), thereby adapting the gene expression
programmes to the demands of the cell environment16–19. We have
reported that SMARCA4 is required to promote cell growth inhi-
bition triggered by corticoids and retinoids in cancer cells6 and that
such effects are enhanced by combination with the pan- histone
deacetylase (HDAC) inhibitor suberanilohydroxamic acid
(SAHA)20. We observed that MYC-amplified but not SMARCA4-
mutant cancer cells were sensitive to these treatments.
Here, we show that cancer cells that lack SMARCA4 have a
defective regulation of H3K27ac/H3K27me3 and exhibit low levels
of KDM6s, indicative of a deficient activity of these demethylases.
This forms not only the basis of the refractoriness to SAHA, but
also sensitises the cancer cells to inhibition of the demethylase
activity of KDM6s, heavily compromising their viability.
Results
Refractoriness to growth inhibition and increase H3K27me3
by SAHA in SMARCA4def cells. We studied the differential
response to SAHA in lung cancer cells with oncogenic activation
of MYC (hereafter referred to as MYCamp) with respect to those
with genetic inactivation of SMARCA4 (hereafter, SMARCA4-
def). The administration of SAHA was more effective at reducing
the growth of MYCamp cells than of SMARCA4def cells (mean of
half-maximum effective concentrations (EC50) of 0.5 and 1.4 µM,
for each group, respectively) (Fig. 1a, b, Supplementary Fig. 1a).
Flow cytometric analysis showed that, in the MYCamp cells,
SAHA blocked cell cycle progression at the G0/G1 or SubG1
phases and increased apoptosis, whereas no changes were
observed in SMARCA4def cells (Supplementary Fig. 1b–d; Sup-
plementary Fig. 2). These effects were not influenced by lung
cancer histopathological subtypes, since they occurred in NSCLC
and SCLC types. The selective sensitivity to SAHA of MYCamp
cells was validated using publicly available datasets including
more than 750 cancer cell lines of different origin and genetic
background (Fig. 1c).
SAHA increases global histone acetylation, favouring an open
chromatin structure and promoting transcriptional activation21.
Transcriptionally active chromatin domains are characterised by a
distinct array of histone marks, e.g., H3K27ac, H3K4me1 and
H3K4me3, whereas H3K27me3 and H2AK119ub are often found at
silent gene loci22,23. We first tested the effects of SAHA in global
H3K27ac and H3K27me3, two different marks on the same residue,
but with opposite functions22,23. As expected, SAHA triggered an
increase in global H3K27ac in all the cells, while we observed an
aberrant accumulation of H3K27me3 in the SMARCA4def cells,
rather than the expected decrease (Fig. 1d). To determine whether
this was due to a defective SMARCA4, we used H1299 cells, which
lack SMARCA4 expression owing to an intragenic homozygous
deletion4, and restored wild type SMARCA4 (H1299-wtSMARCA4),
using a doxycycline-inducible system, as previously reported6. As a
control, we expressed a mutant form that lacked the ATPase domain
(p.Glu668_Gln758del)4 (hereafter referred to as H1299-mutS-
MARCA4). Administration of SAHA did not affect global
H3K27me3 in the H1299-wtSMARCA4 cells, whereas the H1299-
mutSMARCA4 cells underwent an increase in H3K27me3 con-
comitantly with a decrease in global H3K27ac (Fig. 1e). A dominant
negative function of an overexpressed mutant SMARCA4 protein
may underlie this effect in the H1299-mutSMARCA4 cells. Thus, the
absence of a functional SMARCA4 induces defects in the dynamics
of the H3K27me3 mark, following administration of SAHA.
The net levels of H3K27me3 are dictated by the coordinated
action of histone methyltransferases (EZH2) and demethylases
(KDM6A and KDM6B)23. The administration of SAHA did not
alter the levels of EZH2 in most SMARCA4def cells (except in the
H23 cells which showed an increase), indicating that over-
activation of the methyltransferase activity of EZH2 is unlikely to
account for the defects in H3K27me3 triggered by SAHA in these
cells (Fig. 1f; Supplementary Fig. 3a). In contrast, treatment with
SAHA alone reduced EZH2 levels in the MYCamp cells,
consistent with the fact that SAHA triggers inhibition of cell
cycle progression and increases apoptosis in cancer cells with this
genetic context. These effects were enhanced by the addition of
GSK126, an inhibitor of the enzymatic activity of EZH2. Previous
studies have shown that GSK126, alone or combined with HDAC
inhibitors, suppress the growth of the small cell carcinoma of the
ovary hypercalcaemic type (SCCOHT)24,25. Here, the adminis-
tration of GSK126, alone or in combination with SAHA, did not
reduce the proliferation or viability of the SMARCA4def lung
cancer cells (Supplementary Fig. 3b–d), implying that EZH2
activity does not, by itself, cause the refractoriness to cell growth
inhibition by SAHA in SMARCA4def lung cancer cells.
Regulation of KDM6 expression by SMARCA4. The histone
demethylases KDM6A (also known as UTX) and KDM6B (also
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known as JMJD3) have H3K27 as a substrate and play a central
role in the development of some types of tumours23. Searching
the Cancer Cell Line Encyclopedia (CCLE) we found significantly
lower levels of expression of several histone demethylases
(KDMs), including KDM6A and KDM6B, in SMARCA4def
compared with MYCamp cells or with LC cells that are wild type
for SMARCA4 and MYC (Fig. 2a and Supplementary Fig. 4a).
The basal levels of EZH2 were similar in the different groups
(Fig. 2b; Supplementary Fig. 4b). We validated our observations
in a panel of LC cell lines at the mRNA and protein levels in
which, with few exceptions, SMARCA4def cells carry lower levels
of KDM6A and KDM6B, as compared to the MYCamp cells (Fig.
2b, c; Supplementary Fig. 4b). The same observations were made
in lung primary tumours (Supplementary Fig. 4c). Further, the
ectopic expression of the SMARCA4 wild type (H1299-
wtSMARCA4 cells), triggered an upregulation of KDM6A and
KDM6B, albeit subtle. An opposite effect was observed for the
mutant (H1299-mutSMARCA4 cells). The levels of EZH2 were
unaffected (Fig. 2d; Supplementary Fig. 4d). Conversely, in the
MYCamp cells, the depletion of SMARCA4 reduced the levels of
both KDM6s (Supplementary Fig. 4e). Finally, the analysis of the
changes in gene expression from publicly available databases
(Sanger CRISPR) support the down-regulation of several KDMs,
specially KDM6A and KDM6B, following the knockout of
SMARCA4 using CRISPR/CAS9 in a panel of human cancer
cell lines (https://depmap.org/portal/depmap/) (Supplementary
Fig. 4f). Collectively, these observations indicate that a functional
SMARCA4 is required to activate KDM6 expression.
To study the genome-wide effects of wild type and mutant
SMARCA4 and of SAHA on the dynamics of H3K27 modifica-
tion, we performed chromatin immunoprecipitation followed by
sequencing (ChIP-seq) of SMARCA4, EZH2, H3K27ac and
H3K27me3, in the H1299 cell model. No peaks were observed
for SMARCA4 before adding doxycycline, which is consistent
with the absence of SMARCA4 in these cells (Fig. 2e; Supple-
mentary Fig. 5a). The global occupancy of wild type and mutant
SMARCA4 was similar, indicating that ATPase activity does not
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Fig. 1 SAHA reduces growth and H3K27me3 levels in MYCamp, but not in SMARCA4def cancer cells. a Clonogenic assays of the indicated lung cancer
cells, untreated (vehicle) or treated with SAHA. NSCLC, non-small cell lung cancer; SCLC small cell lung cancer. b Distribution and mean of EC50 values for
treatment with SAHA in MYCamp (0.5 µM) and SMARCA4def cells (1.4 µM) (from MTT assays for cell viability; Supplementary Fig. 1). Bars show mean ±
SD; two-sided unpaired Student’s t-test. Values from two independent experiments per cell line are represented. In box-whisker plots, the horizontal band
inside box indicates the median, the bottom and top edges of the box 25th–75th percentiles and the whiskers indicate the min to max. ***P= 0.0002.
c Plot with the comparative half maximal effective concentration (EC50) values for treatment with SAHA (vorinostat) in a panel of 758 cancer cell lines
(from www.cancerrxgene.org database), according to the presence of selected gene alterations, including amplification ofMYC oncogenes and inactivation
of SMARCA4. d–f Representative western blots depicting global levels of the indicated proteins and histone marks (H3K27ac and H3K27me3) in the
indicated cells following treatment with SAHA (d), in the H1299-wtSMARCA4 and H1299-mutSMARCA4 cell models after induction of SMARCA4 (dox,
doxycycline, 1 µg/mL; 72 h), with or without SAHA treatment at 24 and 48 h (e), or in the indicated cells following treatments with SAHA and SAHA plus
GSK126 (f). ACTIN, protein-loading control. A Source Data file is available for this figure.
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Fig. 5a, b). The H3K27ac deposition at promoters was not
affected following restitution of SMARCA4 activity (Fig. 2f).
However, in the SMARCA4 mutant cells, the H3K27ac peaks
were sharper and it was evident a reduction of H3K27ac
downstream of the peaks at promoters, in the gene body regions.
This was in parallel with a strong increase in EZH2 binding to the
DNA in SMARCA4 mutant-expressing cells (Fig. 2e, g;
Supplementary Fig. 5c). The latter observation suggests that the
overexpressed mutant protein has a dominant negative effect.
H3K27ac marks were present in at least 80% of the promoters
bound by SMARCA4 and some also showed EZH2 occupancy
(Fig. 2f; Supplementary Fig. 6a). The increase in EZH2 binding
following expression of the SMARCA4 mutant is consistent with
previous findings that ectopic expression of an SMARCA4-
inactive protein allows the occupancy of PRC1 and PRC2 in CpG















































































- +        - +   
KDM6A KDM6B


















wtSMARCA4   mutSMARCA4
3290    11447          2117 103  386        1328014307       460  28
1907   10136       2590 2160   6719        60075035   7008     1871































































































































ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24618-3
4 NATURE COMMUNICATIONS |         (2021) 12:4319 | https://doi.org/10.1038/s41467-021-24618-3 | www.nature.com/naturecommunications
The administration of SAHA reduced the number of
promoters recruiting SMARCA4 wild type by half, without
producing major changes in global H3K27ac deposition (Supple-
mentary Fig. 5a, b). SMARCA4 does not interact directly with the
DNA, but rather recognises and binds acetylated lysines within
histone H3 and H4 tails27. Given this, the severe reduction of
global H3K27ac deposition observed in SMARCA4 mutant-
overexpressing cells following SAHA treatment, also shown by
western blot (Fig. 1e), could be the reason for the strong
reduction in the global intensity of the SMARCA4 peaks (Fig. 2e).
Conversely, the treatment with SAHA prompted the recruitment
of EZH2 to the DNA and the increase in H3K27me3 deposition
in promoter regions, in mutant and wild type SMARCA4-
expressing cells. However, the effect in the latter cell type was less
dramatic, and we attribute this to the slow rate of H3K27me3
removal (Fig. 2e; Supplementary Fig. 6a). The observation that
SAHA increases EZH2 recruitment and H3K27me3 deposition is
somewhat counterintuitive but may be a compensatory effect to
avoid detrimental high levels of histone acetylation.
SMARCA4 was bound to different KDMs, including KDM2B,
KDM4B, KDM6A and KDM6B, among others, in association with
H3K27ac. However, there was also a concomitant increase in
EZH2 occupancy in the SMARCA4 mutant-expressing cells
(Fig. 2g; Supplementary Fig. 6b). These results support the idea
that SMARCA4 regulates the expression of various KDMs,
including KDM6A and KDM6B, through direct promoter
occupancy. The increase in EZH2 in the promoter of these genes
is consistent with a lack of transcriptional activation and even
some transcriptional repression of these KDMs in the H1299-
mutSMARCA4 cells (Fig. 2d; Supplementary Fig. 4d).
KDM6B depletion mimics the response of SMARCA4def cells
to SAHA. We wondered to what extent the lack of KDM6A or
KDM6B regulation is involved in the greater H3K27me3 and
refractoriness to SAHA in the SMARCA4def cells, and whether
their relative contributions differ. First, we found that the mRNA
levels of the KDM6B were inversely correlated with the EC50 to
SAHA (Supplementary Fig. 7a). Next, using shRNAs, we down-
regulated KDM6A and KDM6B expression in different MYCamp
cells (Fig, 3a; Supplementary Fig. 7b), and noted that, mimicking
the behaviour of the SMARCA4def cells, the reduction in KDM6B
levels, but not of KDM6A, suppressed the ability to inhibit cell
growth (Supplementary Fig. 7c) by SAHA. The depletion of
KDM6B, but not KDM6A, also prevented SAHA from decreasing
overall levels of H3K27me3 deposition (Fig. 3b), hinting at a
more widespread role for KDM6B in the global removal of
H3K27me3. The administration of the small molecule compound
GSK-J428, a very specific inhibitor of KDM6A/KDM6B, has
similar effects, reverting the sensitivity to SAHA in a dose-
dependent manner (Fig. 3c, d) and prevented the SAHA-triggered
global decrease in H3K27me3 in both KDM6s-depleted cells
(Fig. 3b).
These findings suggest that a deficiency in KDM6B account for
the resistance of the SMARCA4def cells to growth inhibition
by SAHA.
Inhibition of KDM6A/B is toxic in SMARCA4def cancer cells.
We hypothesised that the low levels and impaired regulation of
KDM6s expression and the defects in H3K27 modification may
render SMARCA4def cells particularly susceptible to KDM6s
inhibition. We tested the effects of GSK-J4 on the growth of our
panel of cancer cells and found that the drug was more toxic in
the SMARCA4def cells, with a five-fold lower EC50 than in the
MYCamp cells or in the lung cancer cells that are wild type for
both SMARCA4 and MYC (Fig. 4a, b; Supplementary Fig. 8a).
The greater sensitivity of the SMARCA4def cancer cells for GSK-
J4 is supported by studies available from databases (Supplemen-
tary Fig. 8b). For the next stage of the study, we chose to use
GSK-J4 at a concentration of 1 µM (Fig. 4a). We depleted
SMARCA4 in three MYCamp cells and observed a decrease in the
EC50 for GSK-J4, which is further evidence that GSK-J4 is more
toxic in cancer cells with a non-functional SMARCA4 (Fig. 4c).
We also tested the effects of rescuing SMARCA4 on the response
to GSK-J4 using the H1299 cell model. Overexpression of the
mutant SMARCA4 increased sensitivity to GSK-J4 relative to the
restitution of wild type SMARCA4 (EC50, 0.11 µM versus 0.2 µM)
(Supplementary Fig. 8c, d). The toxicity was even greater in the
H1299-mutSMARCA4 than in the parental H1299 cells, sup-
porting the existence of a dominant negative effect of over-
expressing a SMARCA4-mutant protein.
GSK-J4 is a potent inhibitor of KDM6s but can also suppress
the activity of other KDMs, so we investigated how the low levels
of KDM6s suppress cell viability by depleting KDM6A- and
KDM6B. Downregulation of KDM6A or KDM6B inhibited the
growth of the SMARCA4-def cells without affecting the MYCamp
cells (Fig. 4d). In a large scale public CRISPR-based genetic screen
the effect of KDM6s knock down in cell survival of SMARCA4def
cancer cell was also observed (Supplementary Fig. 8e). Moreover,
the lower levels of KDM6A, and to a lesser extent of KDM6B, in
the MYCamp cells, sensitised the cells to the treatment with GSK-
J4 (Fig. 4e, f).
Overexpression of KDM6A and KDM6B in SMARCA4def cells
reverts sensitivity to KDM6A/B inhibition. Next, we aimed to
determine whether the increase in the levels of KDM6A and
KDM6B will revert the sensitivity of the cells to KDM6A/B
inhibition. To do that, we have stably overexpressed the two
different KDM6s in a panel of SMARCA4def cells (H1299, H841,
Fig. 2 SMARCA4 regulates the levels of the KDM6s. a Violin plots comparing levels of the indicated KDMs in SMARCA4def (n= 31), MYCamp (n= 37)
and other (wild type for SMARCA4 and for MYC) (n= 110) lung cancer cell lines (from the Cancer Cell Line Encyclopedia—CCLE at cBioportal). RPKMs
(reads per million). Bars show mean ± SD. Two-sided unpaired Student’s t-test: ***P < 0.001; ****P < 0.0001. bWestern blot depicting endogenous levels of
the indicated proteins in lung cancer cell lines. TUBULIN and ACTIN, protein-loading control. c and d Real-time quantitative PCR of KDM6A and KDM6B
(relative to ACTB) for comparing mRNA levels, for each individual cell line, among the indicated groups of lung cancer cell lines *P= 0.032 (KDM6B) and
*P= 0.016 (KDM6A) (c), or in the H1299-wtSMARCA4 and H1299-mutSMARCA4 cell models (dox, doxycycline, 1 µg/mL; 72 h). *P= 0.029 (KDM6A)
and P= 0.032 (KDM6B) (d). In box-whisker plots, the horizontal band inside box indicates the median, the bottom and top edges of the box 25th–75th
percentiles and the whiskers indicate the min to max. Four and five biological replicates were included for the determination of the KDM6A and KDM6B
levels, respectively, in the H1299 cell model. Bars show mean ± SD. Two-sided unpaired Student’s t-test, e Read count frequency of heatmaps, at ±2 kb
regions centred on the transcriptional start site (TSS), of the indicated proteins and conditions in the H1299 cell model (dox, doxycycline, 1 µg/mL and
SAHA 1 µM, for 72 h). f Venn diagrams representing overlap of SMARCA4, H3K27ac and EZH2 peaks in the indicated cells and under the stipulated
conditions. g Representative snapshots from IGV of ChIP-seq profiles at selected target loci performed in H1299 cell models. A Source Data file is available
for this figure.
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DMS114 and A427) (Fig. 5a). The overexpression of both
KDM6A and KDM6B increased the EC50 to GSK-J4 in all the cell
lines tested. This effect was stronger after overexpressing the
KDM6A (Fig. 5b, c).
Furthermore, we simultaneously overexpressed SMARCA4 and
KDM6A or KDM6B in the H1299 cells (Fig. 5d) and measured
the effects in cell viability upon treatment with GSK-J4. Wild type
SMARCA4 increased the resistance to GSK-J4 mediated by
KDM6A and KDM6B overexpression (Fig. 5e, f).
Together, these findings imply that the lack of SMARCA4
confers vulnerability to KDM6s inhibition on cancer cells, and
that the intrinsically low levels of KDM6s, caused by the defective
function of SMARCA4, underpin these effects.
Anti-tumour effects of GSK-J4 in SMARCA4def lung cancer
orthotopic mouse models. We investigated the ability of the
GSK-J4 compound to suppress tumour growth in vivo. To this
end, we first grew two of the SMARCA4def (DMS114 and H841)
and one MYCamp (DMS273) cell lines subcutaneously into the
back of the mice (n= 3 mice/cell line). Once the solid tumour
had entered the exponential growth phase, mice were euthanized,
and the tumours we minced into small fragments and orthoto-
pically implanted into the lungs of another cohort of mice20,29, to
generate the orthotopic tumours. We randomly assigned the
animals, implanted with each of the tumours, to treatment or
vehicle groups of mice. Treatment with GSK-J4 strongly increased
the overall and median survival of the animals implanted with the
SMARCA4def tumours (DMS114X and H841X) relative to their
matched vehicle group, whereas we found no differences between
vehicle and treated groups in the animals implanted with the
MYCamp tumours (DMS273X) (Fig. 6a). Remarkably, five of the
mice implanted with the H841X and two of those implanted with
the DMS114X and treated with GSK-J4 were alive at the end of
the experiment, but had to be sacrificed despite not having
respiratory difficulties or other symptoms associated with tumour
progression. Our histopathological examination of tumour mas-
ses revealed the existence of large areas of necrosis in the tumours
from GSK-J4-treated mice in comparison with the tumours from
the vehicle-treated mice (Fig. 6b, c; Supplementary Fig. 9). We
also used immunohistochemistry to determine the changes in the
levels of H3K27me3 in the tumour samples following treatment
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Fig. 3 KDM6B depletion mimics the response of SMARCA4-deficient cells to SAHA. a Western blot depicting levels of KDM6s in H460 cells infected
with the non-target short hairpin (shNT) and with different shKDM6A (#63 and #64) and shKDM6B (#676, #976). b Western blot depicting levels
of H3K27me3 and cells infected with the shNT, shKDM6A (#63, #64) or shKDM6B (#676, #976) treated with GSK-J4 and/or SAHA for 72 h.
c Representative clonogenic assays for the indicated cells and treatments. d Viability of indicated cell lines, measured using MTT assays, 5 days after
treatment with increasing concentrations of SAHA and co-treated or not with GSK-J4 at different concentrations. Lines, number of viable cells relative to
the untreated cells. Data are presented as mean ± SD from three replicate cell cultures in two experiments. EC50, half-maximal effective concentration. On
the right, table presenting the combination index (CI) at the indicated concentrations of GSK-J4 (average CI from two independent experiments). CI < 1, CI
= 1 and CI > 1 indicate synergism, additive effect, and antagonism, respectively. A Source Data file is available for this figure.
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H3K27me3 in all the tumours treated with GSK-J4, suggesting
that the compound had effectively reached the tumours (Fig. 6d).
GSK-J4 reduces tumour growth in mice implanted with
SMARCA4def SCCOHT. As previously mentioned, SCCOHT is
a very aggressive and rare type of ovarian cancer that features
inactivation of SMARCA4 in almost all cases9–11. Here, we gen-
erated patient-derived orthotopic xenografts (PDOXs) using the
primary tumours of two SCCOHT patients (OVA250 and
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Fig. 4 SMARCA4def cells are vulnerable to KDM6s inhibition. a Distribution and mean of half-maximal effective concentration (EC50) values for GSK-J4
(MTT assays. Supplementary Fig. 6a) in the indicated groups of cells. Values, from each cell line and from two independent experiments are represented.
Two-sided unpaired Student’s t-test. ****P < 0.0001. In box-whisker plots, the horizontal band inside box indicates the median, the bottom and top edges of
the box 25th–75th percentiles and the whiskers indicate the min to max. b Representative clonogenic assays for the indicated cells and treatments.
c Viability of the indicated cells infected with a short hairpin non-target (shNT) control or with two shRNAs targeting SMARCA4 (#1 and #4), measured
using MTT assays, after treatment with increasing concentrations of GSK-J4 for 5 days. Lines, number of viable cells relative to untreated cells. Data are
presented as mean and SD from three replicates and two experiments. d Representative clonogenic assays for the indicated cells infected with shNT,
shKDM6A (#63, #64) or shKDM6B (#676, #976). e Viability of the indicated cell lines, measured using MTT assays, infected with a non-target (shNT)
control or with two shRNAs targeting KDM6A or KDM6B after treatment with increasing concentrations of GSK-J4 for 5 days. Lines, number of viable cells
relative to the untreated cells. Error bars, mean ± SD from triplicates. f Distribution and mean of the EC50 from two independent experiments per each of
the three LC cell lines. Lines show mean ± SD. P-values were calculated using paired two-tailed Student’s t test. *P= 0.015; ****P < 0.0001; ns, not
significant. A Source Data file is available for this figure.
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ovary30. We used the PDOXs, in their first pass, to derive primary
cancer cell cultures (OVA250L and OVA259L). We confirmed
the presence of biallelic inactivating mutations at SMARCA4 and
the lack of protein in the two patients’ tumour cells and PDOXs
(Fig. 7a; Supplementary Fig. 10a). First, we tested the effects of the
SAHA and GSK-J4 compounds in the primary cultures and
included, as a reference, two commercial epithelial ovarian car-
cinoma cell lines (OVCAR-3 and OVCAR-8), which are wild type
for SMARCA4 (https://cancer.sanger.ac.uk/cell_lines). Treatment
with GSK-J4 strongly suppressed cell viability and clonogenic
capability, exclusively in the OVA250L and OVA259L cells,
whereas SAHA did not affect cell growth (Fig. 7b, c). The levels of
induced cleavage at poly-(ADP-ribose) polymerase 1 (PARP1)
were increased in the SMARCA4def cells indicating apoptosis
(Supplementary Fig. 10b). It was puzzling to observe that the
OVA250L and OVA259L cells had extremely low levels of global
H3K27ac, even after treatment with SAHA. Similar to what
happened in the lung cancer cells, the global basal levels of
H3K27me3 were increased after administration of SAHA
(Fig. 7d).
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Fig. 5 Overexpression of KDM6s reverts sensitivity to KDM6s inhibition. a Western blot depicting levels of ectopic KDM6s and KDM6B in the indicated
SMARCA4def cells overexpressing the indicated proteins. EV Empty vector. b Example of viability of H841 cell line, measured using MTT assays, 5 days
after treatment with increasing concentrations of GSK-J4. Lines, number of viable cells relative to the untreated cells. Data are presented as mean ± SD
from three replicate cell cultures in two experiments. EC50, half-maximal effective concentration. c Distribution and mean of the EC50 from two
independent experiments per each of the three LC cell lines. Lines show mean ± SD. P-values were calculated using paired two-tailed Student’s t test. **P=
0.0017; *P= 0.031. d Western blot depicting levels of KDM6s and SMARCA4 in the H1299 cells overexpressing the indicated proteins. e Viability of
indicated cell lines, measured using MTT assays, 5 days after treatment with increasing concentrations of GSK-J4. Lines, number of viable cells relative to
the untreated cells. Data are presented as mean ± SD from three replicate cell cultures in two experiments. f Distribution and mean of the EC50 from three
independent experiments. Lines show mean ± SD. P-values were calculated using paired two-tailed Student’s t test. **P= 0.0016; ***P= 0.0002; ****P <
0.0001; A Source Data file is available for this figure.
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Next, we investigated the influence of GSK-J4 treatment on the
growth of the OVA250 tumour in vivo. We orthotopically
implanted primary tumours, either treatment-naïve or derived
from mice previously treated with cisplatin (CDDP) (see the
“Methods” section for further details), in the ovary of female nude
mice to generate the OVA250X and OVA250XR tumours,
respectively (Fig. 7e; Supplementary Fig. 10c–f). We observed a
reduction in the size and weight of the tumours from mice treated
with the GSK-J4 inhibitor in the OVA250X model (Fig. 7f).
Although the differences did not reach statistical significance,
histological examination revealed the presence of a few viable
tumour cells in the tumours from mice treated with GSK-J4.
These tissues contained a large amount of fibrosis, instead of the
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because the OVA250X was derived from a primary tumour and
not from cancer cell lines (Fig. 7g). Similar to what was observed
in the lung cancer mouse models, the GSK-J4 treatment triggered
an increase in H3K27me3 (Fig. 7h). Further, the levels of caspase
3, indicative of apoptosis were increased in the SMARCAdef
tumours in those mice treated with GSK-J4 (Fig. 7h). Next, we
generated the OVA250XR tumours to determine the benefits of
GSK-J4 in tumours that have been pre-treated with CDDP, the
standard treatment for SCCOHT. The morphology of the
OVA250XR tumours was similar with that of the primary
tumour and of the OVA250X (Supplementary Fig. 10e). The
OVA250XR showed greater refractoriness to CDDP than did
OVA250X (Supplementary Fig. 10f). The treatment with GSK-J4
significantly decreased tumour growth in the OVA250XR. Taken
together, these observations demonstrate that the KDM6s
inhibitor could constitute a therapeutic option for SCCOHT
patients even after they have become resistant to CDDP
(Supplementary Fig. 10g–i).
Discussion
Here, we present evidence that cancer cells carrying oncogenic
MYC are susceptible to growth inhibition by treatment with the
HDAC inhibitor, SAHA. HDAC inhibitors, including SAHA,
have come to be recognised as biologically active compounds of
value for treating cancers, although their use is currently limited
to some haematological malignancies31. Our current findings
indicate that the pre-selection of patients with tumours in which
any of the MYC family of genes have been genetically activated
will have better response rates to SAHA, which suggests that
SAHA could be used to treat neuroblastomas and lung cancers,
among other types of cancer, in which the MYC genes are
amplified.
Second, we found that lung or ovarian cancer cells with inac-
tivated SMARCA4 not only were refractory to the growth sup-
pression triggered by SAHA, but also aberrantly accumulated
H3K27me3 following the administration of this inhibitor. The
levels of global H3K27ac were low in the SMARCA4def cells, a
characteristic that was accentuated in the SCCOHT cells. We
ruled out a central role for EZH2 methyltransferase activity in the
refractoriness to SAHA in these cells, although the dependency
on a non-catalytic role for EZH2 cannot be completely dis-
counted, as it is known to affect the survival of the SWI/SNF-
mutant cancer cells14. Additionally, we demonstrate that the
transactivation of several lysine demethylases (KDMs), including
KDM6A and KDM6B, is impaired in cells that lack SMARCA4,
leading to a downregulation of basal KDM6s. This, coupled with
inability of these cells to modulate the levels of EZH2 expression
in response to SAHA and, in keeping with other
knowledge6,16–20, is evidence that defective chromatin remodel-
ling in SMARCA4def cells promotes a closed chromatin structure
and a transcriptionally rigid scenario that maintains the
refractoriness of these cells to the appropriate modification of
gene expression upon different stimuli.
Despite the high degree of sequence similarity in the catalytic
domain of KDM6A and KDM6B, these two enzymes have also
some specific roles32. KDM6A is mainly associated with the
demethylation of H3K27me3 at the transcriptional start sites of
the HOX genes upon differentiation stimuli, whereas KDM6B is
involved in inflammation and other, general physiological
processes32. Furthermore, KDM6A, but not KDM6B, is respon-
sible for Kabuki syndrome (KS), an infrequent, inherited disease
that is characterised by neurological, endocrine and autoimmune
disorders33. Here, we found that a deficiency in KDM6B is
responsible for the refractoriness to SAHA in SMARCA4def cells.
Further, a deficiency in KDM6B also accounts for the global
increase in H3K27me3 upon administration of SAHA, which is
consistent with a broader role for KMD6B in H3K27me3
deposition than that of KDM6A34. Non-catalytic activities have
been proposed for the KDM6s which may also account for some
of these differences32.
Considering its potential clinical applicability, the most rele-
vant finding presented here is the great vulnerability of the
SMARCA4def cells to KDM6s inhibition, which was evident in
cell culture and in mouse models with orthotopic transplants of
lung cancer cells and SCCOHTs. Their frequency and poor
prognosis mean that the use of GSK-J4 or similar compounds can
have a great impact on the treatment of SMARCA4-mutant
tumours. Likewise, SCCOHT is an aggressive carcinoma with
rhabdoid characteristics and, though infrequent overall, pre-
dominantly affects young women8–11. Our current results, which
show that GSK-J4 strongly suppresses its growth in vivo,
emphasises the huge potential of KDM6s inhibitors in treating
this disease, which otherwise has very limited treatment options
and, consequently, a dismal prognosis. Currently, there is only
limited, preclinical information about the use of KDM6s inhibi-
tors in cancer treatment. Anti-tumorigenic activities of GSK-J4
have been shown in some leukaemias and in gliomas with H3F3A
mutations, both of which are attributable to the inhibition of
KDM6B35,36. In our case, the depletion of either KDM6A or
KDM6B affected the viability of SMARCA4def cells, suggesting
that, in this context, the depletion of either of them cannot be
compensated. A limiting amount of KDM6s, due the lack of
SMARCA4-mediated transactivation and regulation, seems to
underlie the toxicity to the KDM6 inhibitor, GSK-J4, in SMAR-
CA4def cells. It has also been shown that the KDM6s enhance the
accessibility of the SWI/SNF complex to H3 and promote chro-
matin remodelling37,38 which may also contribute to the strong
dependency of SMARCA4def cells, which rely only in the
SMARCA2-dependent SWI/SNF complex, on these demethylases
for survival. Despite our current findings about the toxicity of the
GSK-J4 compound in SMARCA4def cells, the effects could be
broader, and cancer cells in which other members of the SWI/
Fig. 6 GSK-J4 induces tumour regression of SMARCA4def lung tumours in vivo. a Kaplan–Meier curves showing overall survival for GSK-J4-treated
compared with vehicle control groups of each indicated orthotopically implanted mice model. Panels below, number of mice (n) and mean survival times for
each group of treatment and cell line. P-values from the two-sided log-rank (Mantel–Cox) test of the plots are included. **P < 0.01; ****P < 0.0001. n.s., not
significant. b Representative sections of haematoxylin and eosin (H&E) staining of tumours from the indicated cells, from mice treated with either GSK-J4 or
vehicle. Upper panels, tumour regions are marked within circles. Scale bars, 2.5 mm. The pink areas inside the tumours indicate necrosis. HE heart, LU lung.
Bottom panels, representative sections, at higher magnification, of tumours from the indicated cells and treatments. Scale bars, 50 µm. c Quantification of
necrotic areas. Mean ± SD are indicated for each group. The number of tumours, each from a different individual, were n= 4 in each VH and GSK-J4 treated
groups for the DMS273X mice; n= 4 in the VH and n= 5 in the GSK-J4 groups, for the DMS114X mice and n= 4 in the VH and n= 6 in the GSK-J4 groups,
for the H841X mice. Two-sided unpaired Student’s t-test. ***P= 0.0006; ****P < 0.0001. VH vehicle. d Representative immunostaining of H3K27me3 in
tumours from the indicated cells and treatments. Scale bars, 25 µm. Below, distribution of H3K27me3 staining among tumours (three tumours per cell line
and condition) from the DMS273X, H841X and DMS114X tumours treated with vehicle or GSK-J4. Low (intensity values 1 and 2); high (intensity values 3 and
4) (Supplementary Table 6). Two-sided Fisher’s Exact test. *P < 0.05. A Source Data file is available for this figure.
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SNF-complex or of related pathways are genetically inactivated,
may also be vulnerable to this inhibitor.
Methods
Cancer cell cultures. The cell lines NCI-H841, NCI-H23, NCI-H82, NCI-H69,
NCI-H157, NCI-H1975, NCI-H2170, NCI-H460, NCI-H1963, NCI-H446,
DMS114, NCI-H727, NCI-H228, NCI-H128 and NCI-H1299 cell lines are from
the American Type Culture Collection (ATCC). The DMS273 cell line is from the
European Collection of Authenticated Cell Cultures (ECACC). The Lu165 cells
were obtained from the RIKEN Cell Bank (Japan). The cells were grown under
recommended conditions and maintained at 37 °C in a humidified atmosphere of
5% CO2/95% air. The cell lines were authenticated by genotyping for TP53 and
other known mutations. All cell lines used in this study were mycoplasma-free.
Genomic DNA and total RNA were extracted by standard protocols. One primary
lung cancer cell line PCD11 was derived from malignant pleural effusions39. Two
primary cancer cell lines cultures were derived from orthoxenografts/PDOXs
generated in nude mice from two primary tumours of two SCCOHT patients
(OVA250L and OVA259L) that were obtained from Bellvitge Hospital and the
Catalan Institute of Oncology (ICO) with the approval of the Ethical Committee
(CEIC Bellvitge). Ethical and legal protection guidelines of human subjects,
including informed consent, were followed. Fresh orthoxenografts/PDOXs grown
in the mouse ovaries were collected when mice were sacrificed at passage #1, then
minced with sterile scalpels. Single cells and clumps were transferred to cell culture
plates and maintained in DMEM supplemented with 10% FBS plus 50 U/mL
penicillin and 50 mg/mL streptomycin under standard culture conditions. When
cell colonies with epithelial cell morphology were observed, cells were trypsinized
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passages in vitro. Specific informed consent was obtained from all patients for
tumour implantation into mice, and the study was approved by the IDIBELL Ethics
Committee (No. AAALAC-1155).
Antibodies and western blots. The following primary antibodies were used for
western blots: anti-TUBULIN, T6199 mouse (1/10,000, Sigma Aldrich, St. Louis,
MO, USA); anti-Beta-ACTIN, 13854 (1/20,000 Sigma Aldrich); anti-SMARCA4
49360S (1:1000, Cell Signaling Technology); anti-EZH2 5246S (1:1000, Cell Sig-
naling); anti-H3K27ac D5E4 (1:1000, Cell Signaling) anti-H3K27me3 07-449
(1:1000, Cell Signaling); anti-UTX (KDM6A) D3Q1I (1:1000, Cell Signaling); anti-
KDM6B (JMJD3) #3457 (1:1000, Cell Signaling) for western blots or anti-KDM6B
(JMJD3) ab38113 (Abcam) for immunostaining (see also Supplementary Table 1).
For western blots, whole-cell lysates were collected in a buffer containing 2% SDS
50mM Tris–HCl (pH 7.4), 10% glycerol and protease inhibitor cocktail (Roche
Applied Science). Protein concentrations were determined using a Bio-Rad DC
Protein Assay kit (Life Science Research). Equal amounts of lysates (20 µg) were
separated by SDS–PAGE and transferred to a nitrocellulose membrane that was
blocked with 5% nonfat dry milk. Membranes were incubated with the primary
antibody overnight at 4 °C, then washed before incubation with species-appropriate
IRDye 680CW (925-68022) or IRDye 800CW (925-32213) fluorescent secondary
antibodies (1:10,000 LI-COR, NE, USA) for 1 h at room temperature. Membrane
imaging was performed on the Odyssey Li-Cor CLx i software: Image Studio
Lite v5.2.
Quantitative RT-PCR. To assess mRNA levels of the KDMs in different cells qPCR
analysis was performed. 1 μg of total RNA was reverse-transcribed using Super-
Script™ II reverse transcriptase (Invitrogen) and Random primers (Promega),
according to the manufacturers’ instructions. qRT-PCR was performed in a
Quantstudio Real-Time PCR (Quantstudio Design & Analysis v1.5.1) instrument
using SYBR Green PCR Master Mix (Applied Biosystems). Three biological
replicates were carried out. Primer sequences are provided in the Supplementary
Table 2.
Treatments and shRNAs. Chemicals were obtained from the following sources:
SAHA, suberoyl anilide hydroxamic acid (Cayman Chemical Company, Ann
Arbour, MI, USA); GSK-J4 (Shelleckchem); GSK-126 (Cayman Chemical Com-
pany). shRNAs against SMARCA4, KDM6A and KDM6B were purchased from
SIGMA-MISSION (LentiExpressTM Technology, Sigma-Aldrich) as a glycerol
stock of five pLKO plasmids carrying specific shRNA sequences. A non-target
shRNA (shNT) (Sigma MISSION shRNA non-mammalian control SHC002) was
used as a control. The lentiviruses were generated within the 293T packaging cells.
Oligonucleotide sequences are provided in the Supplementary Table 3.
Flow cytometry. The cells were collected with PBS and the cell suspension was
transferred into the tubes, containing 70% ethanol, and fixed for 2 h. Cells were cen-
trifuged, ethanol was decanted and cells were suspended in 5mL PBS, and then treated
with 1mL propidium iodide (PI)/Triton X-100 staining solution (PI/Triton X-100
staining solution with RNase A, freshly made (to 10mL of 0.1% (v/v) Triton X-100
(Sigma) in PBS add 2mg DNase-freeRNase A (Sigma) and 200 μl of 1mg/mL PI) for
30min at room temperature. Flow cytometry experiments for detecting PI emission
were performed in BD FACSCanto II Cell Analyzer (Becton, Dickinson) and the data
analysis was performed using DNA content frequency histogram deconvolution soft-
ware (FACSDiva v6.1.2). The visualisation graphs were prepared with FlowJo software
version 7.6.
Cell growth analysis and calculation of EC50 and CI. For cell viability assays, cell
lines were incubated in 96-well plates. Before harvesting, cells were treated for
5–7 days with the indicated concentrations of each compound (SAHA, GSK-J4,
GSK-126) or combinations. For the assays, 10 µL of a solution of 5 mg/mL MTT
[3-(4,5)-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide] (Sigma Chemi-
cal Co.) was added. After incubation for 3 h at 37 °C, the medium was discarded,
the formazan crystals that had formed were dissolved in 100 µL of lysis buffer (50%
N-N-dimethylformamide in H2O, 20% SDS, 2.5% glacial acetic acid, NaOH 5mol/
L, pH 4.7), and absorbance was measured at 596 nm. Results are presented as the
median of at least two independent experiments performed in triplicate for each
cell line and for each condition. For EC50 calculations, cells were treated with each
drug and their various combinations for 5 days. Estimates of EC50 were derived
from the dose response curves. To assess the drug concentration effect and to
calculate the combination index (CI), cells were plated in 96-well plates and
incubated with a concentration of SAHA ranging from 0.07 to 10 μM (0.07, 0.15,
0.3, 0.6, 1.25, 2.5, 5.0 and 10 μM), and the same for GSK-J4 for 5 days. MTT assays
were performed and the EC50 was determined by fitting the dose-response curve
utilising the CompuSyn software. The CI values for each dose and the corre-
sponding effect level were calculated. The CI offers a quantitative definition for
drug combinations in which CI < 1, CI= 1 and CI > 1 indicate synergism, an
additive effect, and antagonism, respectively.
For clonogenic assays, the plates were seeded with 5000 cells from each cell line,
then treated with SAHA (1 µM), GSK-J4 (1 µM) or GSK-126 (1 µM) for 5 days.
Cells were stained with crystal violet solution (0.5% Crystal Violet in 25% of
methanol).
ChIP-sequencing. For ChIP, cells were grown in P-150 cm cell dishes and fixed
with 1% methanol-free formaldehyde (Thermo Scientific) for 10 min at room
temperature, then quenched by 125 mmol/L glycine for 15 min at room tem-
perature, washed with ice-cold PBS twice and centrifuged at 200 × g, 4 °C for 5 min.
The pellet was resuspended in 1 mL of cell lysis buffer (10 mmol/L Tris–HCl, 10
mmol/L NaCl, 0.5% NP-40, protease inhibitor) and kept at 4 °C, rotating for 30
min. After centrifugation, the pellet was resuspended in 1 mL of nuclear lysis buffer
(1% SDS, 10 mmol/L EDTA, 50 mmol/L Tris-HCl pH 8.0, protease inhibitor) and
kept at 4 °C for 60 min. After another centrifugation, the lysate was sonicated with
a Covaris M220 instrument to yield chromatin fragments of an average size of
0.25–1.00 kb, and then frozen at −20 °C for 30 min. The chromatin was thawed on
ice and centrifuged at 2500 × g. For each ChIP reaction, 60 μL of Magna ChIP™
Protein A+G Magnetic Beads (Merck Millipore) was used in accordance with the
manufacturer’s protocol. Before addition of the sheared chromatin to the beads,
Triton X-100 and Na-deoxycholate was added to a final concentration of 10% each.
1% of the chromatin volume was used for input. At least two independent ChIP
experiments were performed.
Immunoprecipitated chromatin was deep-sequenced in the Genomics Unit of
the Centre for Genomic Regulation (CRG, Barcelona, Spain) using the Illumina
HiSeq 2500 system and HiSeq Control Software (HCS) 2.2.68 software (Illumina).
Briefly, library preparation included end-repair, generation of dA overhangs,
adapter ligation, size selection and removal of non-ligated adapters by agarose gene
electrophoresis and amplification (18 cycles) before loading the samples into the
sequencer.
For ChIP-sequencing data analysis, reads were aligned to the human reference
genome hg38, using Bowtie v1.2.2, with default parameters and disallowing multi-
mapping (–m 1)40. PCR duplicates were removed using PICARD (http://
broadinstitute.github.io/picard/). Ambiguous and multi-mapped reads were
discarded. Peaks were called using MACS2 v2.1.141. To avoid false positives, peaks
were discarded if they were present in the ChIP-seq of SMARCA4 in the
SMARCA4-deficient cells. Genomic peak annotation was performed with the R
package ChIPpeakAnno v3.15, considering the region ±2 kb around the TSS as the
promoter42. All analyses considered peaks overlapping with promoter regions,
unless otherwise specified. Peak lists were then transformed to gene target lists.
Fig. 7 GSK-J4 reduces cancer cell viability of SCCOHT orthotopically implanted in mice. a Chromatogram depicting changes in SMARCA4, at the genomic
DNA level, in the SCCOHTs of two patients. The alterations were biallelic, confirming the complete inactivation of SMARCA4. A normal reference DNA is also
included. b Representative clonogenic assays for the indicated cells and treatments. c Percentage of viable cells of the indicated cells, measured using MTT
assays, after treatment with increasing concentrations of GSK-J4 for 5 days. Lines show the number of viable cells relative to the total number at 0 h. Error
bars, mean ± SD from three replicates. EC50 half-maximal effective concentration. d Western blot of the endogenous levels of the indicated proteins and
cancer cells. TUBULIN, protein-loading control (48 h treatments, except 24 h in the GSK-J4 for the OVA250L cells). e Schematic representation of different
models and treatments in mice developed from the OVA-250 tumour. SCCOHT small cell carcinoma of the ovary, hypercalcemic type. CDDP cisplatin. Figure
schematics were generated using https://smart.servier.com/ (https://creativecommons.org/licenses/by/3.0/). f Left panel, gross pathological photographs
at necropsy of the ovarian tumours that arose in mice treated with vehicle (n= 5) or GSK-J4 (n= 7). Right panels, volume and weight of each tumour. Two-
sided unpaired Student’s t-test. n.s. not significant. g Representative sections of H&E staining of tumours from the group of mice treated as indicated (n= 5 in
each group). Pink areas inside the tumours indicate fibrosis. Scale bars, 2.5 mm; Lower panels, magnification of the areas indicated (rectangle); scale bar, 50
µm (above) and 25 µm (below); Lower right panel, quantification of fibrotic areas. Two-sided unpaired Student’s t-test. Error bars, mean ± SD from replicates.
****P < 0.0001. h Representative immunostaining of H3K27me3 and of CASPASE-3 for OVA250X tumours treated with vehicle or GSK-J4. Scale bars, 25 µm.
The quantification of the immunostaining is provided in Supplementary Table 6. A Source Data file is available for this figure.
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For heatmap and intensity plot representation of ChIP-seq signal, bedgraph files
were generated using the makeUCSCfile function in HOMER with default
parameters normalising for differences in sample library size, and BigWig files were
generated using the function bedGraphToBigWig from UCSC. Heatmaps were
derived using the functions computeMatrix, in a window of ±2 kb around the
centre in the TSS, and plotHeatmap from deepTools43 (version 3.5).
Construction of expression vectors and infections. The complete KDM6A
cDNA (NM_021140.4) was PCR-amplified, from a retrotranscribed human RNA
pool (Agilent Technologies, Santa Clara, CA, USA) using Phusion High-Fidelity
DNA Polymerase (Thermo Scientific, Waltham, MA, USA) following standard
protocols. The cDNA fragments were cloned into the pLVX-IRES-ZSGreen vector
(Clontech), between the XhoI and NotI endonuclease restriction sites, following the
manufacturer’s instructions. For the KDM6B, the complete KDM6B coding region
(ENSG00000132510.10) was PCR-amplified, from a human DNA pool (Agilent
Technologies, Santa Clara, CA, USA) using Phusion High-Fidelity DNA Poly-
merase (Thermo Scientific, Waltham, MA, USA), following standard protocols.
The fragment was cloned into the pCDNA4/TO vector (Invitrogen), between the
KpnI and XhoI endonuclease restriction sites, following the manufacturer’s
instructions. The KDM6A and KDM6B inserts were then Sanger-sequenced. All
the primers used are listed in Supplementary Tables 4 and 5. For KDM6A ectopic
expression, the cells were infected with lentiviruses derived from the pLVX-IRES-
ZSGreen vector and then selected by sorting GFP positive cells, using an BD
FACSArea (Becton, Dickinson). For KDM6B ectopic expression, the cells of
interest were transfected with a pCDNA4/TO-KDM6B construct and clones
expressing KDM6B were selected with Zeocin (InvivoGen) and pooled.
Generation of orthotopic tumour models and treatments. Male and female
athymic nu/nu mice (ENVIGO) aged 4–5 weeks were maintained in a sterile
environment before use in the lung cancer orthotopic experiments. Female athymic
nu/nu mice (ENVIGO), 4–6 weeks old, were used for the ovarian cancer orthotopic
studies. The animals were housed in individually ventilated cages on a 12-h
light–dark cycle at 21–23 °C and 40–60% humidity. Mice were allowed free access
to an irradiated diet and sterilised water. All animal experiments were approved by
the IDIBELL Ethical Committee under protocol 9111 approved by the Government
of Catalonian, AAALAC accredited Unit 1155, and performed in accordance with
guidelines stated in the International Guiding Principles for Biomedical Research
Involving Animals, developed by the Council for International Organizations of
Medical Sciences (CIOMS). To generate orthotopic lung tumour xenografts the cell
lines were injected subcutaneously into the back of the mice (n= 3 mice/cell line).
Once the solid tumour had entered the exponential growth phase, mice were
sacrificed, the tumour was isolated under sterile conditions, and the non-necrotic
areas were selected and minced in small fragments of 2–3 mm3. These were then
orthotopically implanted in the lung parenchyma20,29. On day 15, the mice were
randomised and intraperitoneally treated with GSK-J4 (50 mg/kg/day for each
mouse) or corresponding vehicle only. For the lung orthotopic models, in most
cases the animals were sacrificed when they displayed serious respiratory difficulty,
which was subsequently confirmed to be associated with lung tumour growth.
Orthoxenografts or PDOXs of SCCOHT were generated. The primary tumour
specimens for the two primary SCCOHT samples were freshly obtained at Hospital
Universitario de Bellvitge (Hospitalet de Llobregat, Barcelona, Spain). The study
was approved by the Institutional Review Board, and written informed consent was
obtained from both patients. The orthotopic ovarian tumours were engrafted in
mice, following an established protocol30. Briefly, non-necrotic tissue pieces (2–3
mm3) from resected carcinoma were selected and placed in DMEM (BioWhittaker)
supplemented with 10% FBS and penicillin/streptomycin at room temperature.
Under isofluorane-induced anaesthesia, animals were subjected to a lateral
laparotomy, their ovaries exposed, and tumour pieces anchored to the ovary
surface with prolene 7.0 sutures. Tumour growth was monitored 2 or 3 times per
week and when the tumour had reached a sufficient size, it was harvested, cut into
small fragments, and transplanted into between two and four new animals.
Engrafted tumours (named OVA250X) at early mouse passages were cut into 6–8
mm3 pieces and stored in liquid nitrogen in a cryopreservation solution of 90% FBS
and 10% dimethyl sulfoxide, awaiting subsequent implantation.
To generate the cisplatin-resistant ovarian xenograft mouse model,
orthotopically engrafted OVA250X tumours at passage#1 were allowed to grow (n
= 3 mice) until palpable intra-abdominal masses were noted. Cisplatin was i.v.-
administered to the animals (cycle #1, 3, 5 mg/kg dose) for 3 consecutive weeks
(days 0, 7 and 15; cycle#1 of treatment) (Supplementary Fig. 9b). Post-cisplatin
tumours at relapse were harvested and engrafted in new animals. This process of
cisplatin treatment was repeated up to four times by treating tumour-bearing mice
with stepwise-incremental doses of cisplatin: cycle #2, 4 mg/kg; cycle #3, 5 mg/kg
and cycle #4, 5 mg/kg (see Supplementary Fig. 9b). Cisplatin-resistant tumours
were obtained (OVA250XR). At doses higher than 3.5 mg/kg, signs of cisplatin
induced some toxicity that were ameliorated by 2 days administration of saline
containing 5% glucose. Mice were transplanted with fragments of OVA250X and
OVA250XR tumours, and when tumours reached a homogeneous palpable size
were randomly allocated into the treatment groups (n= 3-7 mice/group): (i)
Placebo; (ii) GSK-J4 (50 mg/kg) and (iii) cisplatin (3.5 mg/kg); drugs were
administered once a day, 5 days per week, for 4 consecutive weeks. Animals were
sacrificed on day 21 of treatment, and their ovaries dissected out and weighed.
Representative fragments were either frozen in nitrogen or fixed and processed for
paraffin embedding.
Histopathology and immunostaining. For histological analysis, tumours were
fixed and embedded in paraffin. Necrosis/fibrosis were morphological assessed
after staining with haematoxylin and eosin (H&E), using standard protocols, and
then examined by light microscopy in a blinded fashion. For immunostainings, 4-
μm-thick paraffin-embedded sections of lung and ovarian tumour samples were
deparaffinized overnight at 62 °C and then immersed in xylene. Samples were
rehydrated and, after microwaving with Tris/EDTA pH 9.0 for antigen retrieval,
endogenous peroxidase was inhibited with a 3% hydrogen peroxide solution,
blocked in 10% goat serum and incubated with primary antibodies overnight at 4 °
C (Supplementary Table 1). HRP-conjugated polyclonal goat (anti-mouse and anti-
rabbit) secondary antibodies (NeoStain ABC Kit, NeoBiotech) were used in 1-h
incubations at room temperature. Labelling detection was done using an
ImmPACT DAB Peroxidase (HRP) Substrate kit (Vector Laboratories, Burlingame,
CA, USA), and tissue sections were counterstained with haematoxylin. Once
dehydrated in an ethanol battery and cleared in xylene for 1 h, samples were
mounted with coverslips with DPX mounting medium (Merck Millipore, Darm-
stadt, Germany). Sections were evaluated under a Leica DM1000 microscope by
two independent observers in a blind fashion. Areas of necrosis/fibrosis were
quantified using Photoshop (version 2021). The scoring criteria for determining
H3K27me3 staining were based on the staining intensity (four categories, 1–4)
(Supplementary Table 6). The mean of values from three independent evaluators
was determined.
Statistical analysis. Student’s t-tests, EC50 calculations, Kaplan–Meier estimates
and log-rank (Mantel–Cox) test were performed using Prism software (GraphPad
Prism 9). Values of P <5% were considered statistically significant. The statistical
methods used for each analysis are specified in the figure legends.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The ChIP-seq raw data obtained in this study has been uploaded to the Gene Expression
Omnibus-GEO (NCBI), under accession number GSE155129. Uncropped western blot
images are also present in a Source Data file. Databases/Datasets used in the study were:
cBioPortal for Cancer Genomics, Cancer Cell Line Encyclopedia-CCLE (https://www.
cbioportal.org/study/summary?id=ccle_broad_2019), COSMIC-Catalogue of Somatic
Mutations in Cancer (https://cancer.sanger.ac.uk/cell_lines), DepMap Portal-Cancer
Dependency Map (https://depmap.org/portal/achilles/), Genomics of Drug Sensitivity in
Cancer database (https://www.cancerrxgene.org/compound/Vorinostat/1012/overview/
ic50, https://depmap.org/portal/compound/GSK-J4?tab=dependency). The authors
declare that other data supporting the findings of this study are provided in the
Supplementary Information/Source Data file. Source data are provided with this paper.
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